Cargando…

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea

The present study investigated the risk of active tuberculosis in patients with inflammatory bowel disease (IBD) treated with vedolizumab or ustekinumab, in actual clinical settings in a country with an intermediate tuberculosis burden. The medical records of 238 patients with IBD who received vedol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Myeong Geun, Ye, Byong Duk, Yang, Suk-Kyun, Shim, Tae Sun, Jo, Kyung-Wook, Park, Sang Hyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001185/ https://www.ncbi.nlm.nih.gov/pubmed/35411727 http://dx.doi.org/10.3346/jkms.2022.37.e107

Ejemplares similares

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease
por: Kang, Jieun, et al.
Publicado: (2018)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab
por: Kim, Min Kyu, et al.
Publicado: (2023)

Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
por: Lee, Jin Wook, et al.
Publicado: (2021)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
por: Lee, Jae Yong, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
por: Mitrova, Katarina, et al.
Publicado: (2021)

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors
por: Kim, Kyuwon, et al.
Publicado: (2021)

Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea
por: Lee, Ho-Su, et al.
Publicado: (2016)

Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea
por: Kang, Bo Hyoung, et al.
Publicado: (2017)

Primary Sclerosing Cholangitis with Inflammatory Bowel Disease in Korean Children
por: Yoon, Jisun, et al.
Publicado: (2015)

The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study
por: Ye, Byong Duk, et al.
Publicado: (2021)

Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
por: Jeffrey, Angus W., et al.
Publicado: (2023)

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
por: Sunny, Julee, et al.
Publicado: (2022)

Bullous Wells Syndrome Induced by Ustekinumab
por: Kim, Yeona, et al.
Publicado: (2023)

Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea
por: Choi, Su Jin, et al.
Publicado: (2021)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
por: Kim, Seong Kyun, et al.
Publicado: (2021)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Impact of Crohn’s Disease on the Survival of Patients with Small-Bowel Adenocarcinoma in Korea: A Bicenter Cohort Study
por: Kim, Kyuwon, et al.
Publicado: (2023)

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Prevalence of Latent Tuberculosis Infection among Medical Students in South Korea
por: Jung, Da Ho, et al.
Publicado: (2012)

Clinical features of enteric and colo-duodenal fistula in patients with Crohn’s disease
por: Lee, Jun Su, et al.
Publicado: (2023)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
por: Vu, Michelle, et al.
Publicado: (2023)

Revision of the National Action Plan in Response to Poliovirus Importation in Korea
por: Park, Young-Joon, et al.
Publicado: (2013)

Diffusion-Weighted MR Enterography to Monitor Bowel Inflammation after Medical Therapy in Crohn's Disease: A Prospective Longitudinal Study
por: Huh, Jimi, et al.
Publicado: (2017)

Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases
por: Hong, Hee Seung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ghne1sov96k1qt5e9k6v3t361